BayWa's Restructuring Stalls as Billion-Euro Gap and Creditor Standoff Deepen

A critical €107 million payment due at the end of April is set to test the fragile restructuring of German agricultural and energy group BayWa. The proceeds from the sale of its Cefetra unit, while providing a cash infusion, are merely a bargaining chip in high-stakes negotiations with creditor banks. The talks have stalled over a newly identified balance sheet gap of up to one billion euros, driving a wedge between the company's main owners and its lenders.

The core issue remains unchanged: the total debt pile of approximately six billion euros. A proposed solution involving a debt-to-equity swap, which would convert loans from some 175 cooperative banks into equity, is being resisted. Lead institutions like DZ Bank have dismissed such ideas as premature, highlighting the vast distance between the parties. Without the banks' agreement to extend a forbearance agreement until autumn 2026, the entire rescue plan loses its operational foundation.

Further complicating the debt reduction strategy is the crumbling valuation of a key asset. The planned sale of the renewable energy subsidiary BayWa r.e., originally projected to raise an estimated €1.7 billion by 2028, has been derailed. Changes to US legislation, specifically the "One Big Beautiful Bill Act" which slashed subsidies for solar and wind projects, have forced a drastic reassessment. The original EBITDA forecast of €230 million for 2028 has been scrapped; BayWa now expects only €150 million by 2030. This collapse in projected earnings has blown a massive hole in the funding plan.

The financial strain is starkly evident in the banks' own accounts. They have already taken substantial write-downs, including a 60% impairment on a €220 million promissory note from Bavarian cooperative banks—a loss of €132 million booked in the 2024 accounts.

Should investors sell immediately? Or is it worth buying BayWa?

Investor patience is wearing thin, reflected in a steep share price decline. The stock closed at €13.50 on Friday, marking a 32.5% loss over the past twelve months and a nearly 20% drop since the start of the year. Technically, the chart appears extremely strained with a 14-day RSI of 80.0, and the shares trade roughly 21% below their 200-day moving average.

Attention now turns to the next major asset sale: the divestment of the nearly 74% stake in New Zealand fruit grower T&G Global. Goldman Sachs has been managing the process since March 2026. T&G, which returned to profitability with a net income of $16 million on revenue of $1.3 billion in 2024, is considered an attractive asset with brands like Envy and Jazz apples. However, the process is complicated by minority shareholder Joy Wing Mau Group in Hong Kong, and the expected €300 million in proceeds would do little to bridge the overall funding shortfall. To date, BayWa has secured only €1.3 billion of its €4 billion restructuring target.

The complexity of revaluing major assets like BayWa r.e. is causing significant operational delays. The company's annual and consolidated financial statements for 2025 are now expected to be delayed until the fourth quarter of 2026, depriving investors of a reliable basis for fundamental assessment. Governance is also in flux, with three supervisory board members having recently departed and no date set for a shareholder meeting to confirm their successors.

BayWa at a turning point? This analysis reveals what investors need to know now.

The Cefetra payment is more than an accounting formality. It represents the first measurable test of whether BayWa's restructuring roadmap is credible and whether its creditors are willing to grant the beleaguered conglomerate the time it desperately needs.

Ad

BayWa Stock: New Analysis - 12 April

Fresh BayWa information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BayWa analysis...

en | DE0005194005 | BAYWAS | boerse | 69131816 |